| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | -$505.6M | ROE | −64.82% |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
Immunovant is a clinical-stage immunology company developing targeted therapies for people with autoimmune diseases. Its lead candidate is IMVT-1402, a human monoclonal antibody that inhibits the neonatal fragment crystallizable receptor, being developed for conditions including Graves' disease, rheumatoid arthritis, Sjogren's disease, cutaneous lupus erythematosus, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company operates as a subsidiary of Roivant Sciences.
| Market Cap | $7.99B | Trading Days | 1653 |
| 52W High | 41.23 |
| 52W Low | 14.32 |
| % Off High | −5.65% |
| YTD | 53.03% | 1Y | 132.10% |
| 3Y | 72.66% | 5Y | 260.52% |
| Since incept. (ann.) | 14.42% |
| Ann. Volatility (1Y) | 62.10% | Ann. Volatility (3Y) | 78.75% |
| Sharpe (1Y) | 1.68 | Sharpe (3Y) | 0.56 |
| Max Drawdown (1Y) | −17.19% | Max Drawdown (3Y) | −69.88% |
| Beta (3Y, vs SPY) | 0.41 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| PCVX | Vaxcyte, Inc. | $7.88B | — |
| APGE | Apogee Therapeutics, Inc. | $8.14B | — |
| RGEN | REPLIGEN CORP | $8.20B | 169.0 |
| KYMR | Kymera Therapeutics, Inc. | $8.73B | — |
| IBRX | ImmunityBio, Inc. | $7.30B | — |
| QGEN | QIAGEN N.V. | $9.17B | — |
| HALO | HALOZYME THERAPEUTICS, INC. | $9.90B | 32.6 |
| CGON | CG Oncology, Inc. | $6.41B | — |
| KRYS | Krystal Biotech, Inc. | $10.74B | 53.3 |
| SRRK | Scholar Rock Holding Corp | $5.92B | — |
| TECH | BIO-TECHNE Corp | $11.28B | 156.7 |
| TWST |
| $5.51B |
| — |
